Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 7/20 | 0.84 |
| ▸ | PIM1 | P11309 | 1/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.76 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.76 |
| ▸ | MMP13 | P45452 | 2/20 | 0.74 |
| ▸ | MMP3 | P08254 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.71 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.71 |
| ▸ | CLK1 | P49759 | 1/20 | 0.71 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.71 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.71 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.71 |
| ▸ | GSK3B | P49841 | 2/20 | 0.70 |
| ▸ | NAT1 | P18440 | 2/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1726213 | 1.00 | ADAMTS5 (0.84) | ADAMTS5PIM1AKR1B1PIM2MMP13 | |
| SCHEMBL17140247 | 1.00 | ADAMTS5 (0.84) | ADAMTS5PIM1AKR1B1PIM2MMP13 | |
| SCHEMBL12961151 | 0.92 | MEN1 (0.85) | ADAMTS5PIM1AKR1B1PIM2MMP13 | |
| SCHEMBL18103023 | 0.91 | ADAMTS5 (1.00) | ADAMTS5PIM1AKR1B1PIM2MMP13 | |
| SCHEMBL8312114 | 0.86 | ADAMTS5 (0.75) | ADAMTS5PIM1AKR1B1PIM2MMP13 | |
| SCHEMBL18103036 | 0.86 | MEN1 (0.71) | ADAMTS5PIM1AKR1B1PIM2MMP13 | |
| SCHEMBL1250160 | 0.86 | PIM1 (1.00) | ADAMTS5PIM1AKR1B1PIM2MEN1 | |
| SCHEMBL1250158 | 0.86 | PIM1 (1.00) | ADAMTS5PIM1AKR1B1PIM2MEN1 | |
| SCHEMBL7556271 | 0.86 | PIK3CG (0.84) | ADAMTS5PIM1PIM2MMP13MMP3 | |
| SCHEMBL7556274 | 0.86 | PIK3CG (0.84) | ADAMTS5PIM1PIM2MMP13MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20170137862-A1 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | Life Technologies Corporation | 2017-05-18 | — | — | US | disclosed |
| US-9518285-B2 | Chemiluminescent compositions, methods, assays and kits for oxidative enzymes | Life Technologies Corporation (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150284766-A1 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | Life Technologies Corporation | 2015-10-08 | — | — | US | disclosed |
| US-9067910-B2 | Chemiluminescent compositions, methods, assays and kits for oxidative enzymes | Life Technologies Corporation (US) | 2015-06-30 | — | — | US | disclosed |
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | disclosed |
| US-20120100566-A1 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | Life Technologies Corporation (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | disclosed |
| US-7872027-B2 | Low molecular weight Myc-max inhibitors | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-01-18 | — | — | US | disclosed |
| WO-2010101839-A2 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | Life Technologies Corporation (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| US-5716975-A | NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| US-5661168-A | ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | disclosed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | ADAMTS5 2358/4885PIM1 2196/4885AKR1B1 3876/4885 |
| US-20150284766-A1 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | AOX1, CAT, LPO | ADAMTS5 1561/4885PIM1 2511/4885AKR1B1 77/4885 |
| US-20120100566-A1 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | CBR1, AOX1, POR | ADAMTS5 1953/4885PIM1 2764/4885AKR1B1 41/4885 |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, UGT1A1 | ADAMTS5 457/4885PIM1 2506/4885AKR1B1 248/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | ADAMTS5 2358/4885PIM1 2196/4885AKR1B1 3876/4885 |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, CYP3A4 | ADAMTS5 1450/4885PIM1 3492/4885AKR1B1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.